Lialda® / Mezavant® / Mesavancol® is a proprietary formulation for targeting the release of high concentrations of Mesalazine (5-aminosalicyd acid or 5-ASA), based on the MMX® technology, to the colon. Lialda® / Mezavant® is indicated for the induction and maintenance of clinical and endoscopic remission in patients with active, mild-to-moderate Ulcerative Colitis and is, to Cosmo’s knowledge, the first available once daily Mesalazine treatment.

Lialda® / Mezavant® / Mesavancol® is an oral tablet formulation able to deliver Mesalazine directly into the lumen of the colon; the specific drug dissolution profile increases the colonic specific disposition of Mesalazine, reduces the pre-colonic systematic absorption and allows the product to be especially effective for the treatment of both proximal and distal Ulcerative Colitis.

Through the application of the MMX® technology, patients taking Mesalazine in non-acute phases will have to take about two tablets a day and during acute phases of Ulcerative Colitis about three to four tablets a day. The expected reduction in the number of tablets to be taken in comparison to standard oral administration of Mesalazine facilitates increased patient compliance.

Cosmo’s patent expires in the year 2020.



Back to top